SCN1A and Dravet syndrome: An inactivated Cas9 enzyme fused to a transcriptional activator brought to the promoter region of Scn1a led to a better control of seizures in a haploinsufficient DS mouse model (Colasante and others 2020; Yamagata and others 2020).